Drug intelligence / Profile preview

A49-Mel

Development stage: Phase 2
Lead developer: Assistance publique - Hôpitaux de Paris
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**A49-Mel** is an investigational therapeutic peptide cancer vaccine formulation for newly diagnosed glioblastoma. It comprises a peptide epitope derived from **protein tyrosine phosphatase receptor type Z1** adsorbed onto synthetic melanin. The formulation is intended to induce PTPRZ1-specific antitumor T-cell immunity against PTPRZ1-expressing glioblastoma cells. In the NAVIG-1 study, A49-Mel is administered by subcutaneous injection during the Phase 1 dose-escalation component together with A52-Mel and the separately administered TLR9 agonist adjuvant litenimod.

Other names: Peptide A49 associated to melanin

Targets

TLR9 (Toll-like receptor 9)TERT (Telomerase)PTPRZ1 (Protein tyrosine phosphatase receptor type Z1)

Beyond the preview

Go deeper on A49-Mel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A49-Mel.

Explore the full profile